INTERFERON ENHANCED INTRAPERITONEAL RADIOIMMUNITY FOR OVARIAN CANCER

共有29名患者参加了这项I期试验，该试验给出了 177Lu-CC49联合紫杉醇化疗(与 在放射免疫治疗前给予干扰素以增强抗原 肿瘤的表达)。有资格参加这项试验的患者是 接受了除髓手术和辅助化疗，以及 在第二次手术或成像扫描中有残留的疾病，或者有 后来又复发了。先前的一项研究已经确定了177 Lu的MTD- CC49为45mci/m2。当与干扰素一起使用时， 177Lu-CC49为40mci/m2。目前的研究使用了80%的剂量 177Lu-CC49+干扰素MTD剂量与递增剂量 腹腔注射紫杉醇。令人振奋的反应出现在一些 已被评估的患者，研究仍在进行中。

A total of 29 patients have ben entered on this phase I trial which gives a combination of 177Lu-CC49 in conjunction with Taxol chemotherapy (with interferon being given prior to radioimmunotherapy to enhance antigen expression of the tumor). Patients eligible for this trial are those who have received debulking surgery followed by adjuvant chemotherapy, and have residual disease on second look surgery or on imaging scans, or have subsequently relapsed. A previous study had determined the MTD of 177Lu- CC49 as being 45 mCi/m2. When administered with interferon the MTD of 177Lu-CC49 has been 40 mCi/m2. The current study uses an 80% dose of the MTD dose of 177Lu-CC49+interferon along with escalating doses of intraperitoneal Taxol. Encouraging responses have been seen in some of the patients who have been evaluable, and the study is ongoing.